In NSCLC, it directly targets p85α, IGF1, and IGF-1R, resulting in a decrease of pAKT signaling and downstream pFoxo3a activity, thus preventing proliferation, and promoting in vitro and in vivo lung cancer apoptosis [79]. Here, IGF1R is linked to lung carcinoma.